Quick question — when would retatrutide actually be available? The Phase 2 data is from 2023. How long does Phase 3 take? And would it compete with tirzepatide or be positioned differently?

Phase 3 (TRIUMPH program) is currently enrolling and expected to read out in 2026-2027. If positive, FDA submission would follow, with potential approval in 2027-2028 at the earliest. This is Eli Lilly's pipeline, so it would sit alongside tirzepatide (Mounjaro/Zepbound) in their portfolio.

Positioning will be interesting. Lilly likely envisions retatrutide as the "next generation" option for patients who need more weight loss than tirzepatide provides, or specifically for patients with MASH/MASLD where the glucagon component adds value. It's unlikely they'd position it as a direct replacement for tirzepatide — different patient segments.

The competitive landscape is moving fast. By the time retatrutide is approved, we'll also have data on amycretin (Novo Nordisk's amylin/GLP-1 co-agonist), CagriSema, oral semaglutide 50 mg, and possibly survodutide. The obesity pharmacotherapy market is going to look very different in 3 years.

Good discussion. Let me summarize the key takeaways for the thread:

1. Retatrutide Phase 2 shows the highest weight loss ever achieved with pharmacotherapy (~24% at 48 weeks, still declining)
2. The triple agonism (GIP/GLP-1/glucagon) appears to have additive benefits, particularly for liver fat reduction
3. Phase 2 data requires confirmation in larger Phase 3 trials — don't take these numbers as the final word
4. Safety profile is acceptable but GI side effects are higher than current agents
5. Body composition data is needed and is a major outstanding question
6. Phase 3 readout expected 2026-2027; potential approval 2027-2028

We'll update this thread as the TRIUMPH Phase 3 data emerge. In the meantime, let's maintain scientific rigor and not extrapolate Phase 2 results beyond what the data support.